Table 3.
Outcomes evaluated in the meta-analysis: BEVA vs schemes without BEVA (no BEVA)
| Outcomes | Studies n (references) | Participants | Estimated effect [95% CI] (pvalue) | I2 (%) | p value |
|---|---|---|---|---|---|
| Overall survival (months) | 16 [13, 42, 71, 73, 74, 77, 78, 81–87] | 11,094 | 4.07 [1.69 to 6.45] (p < 0.001) | 81 | 0.00001 |
| BEVA + CT vs CT alone | 4 [13, 71, 78, 82] | 4842 | 2.83 [− 1.76 to 7.41] (p = 0.23) | 87 | 0.00001 |
| BEVA + FOLFIRI vs FOLFIRI | 1 [13] | 267 | 2.20 [− 4.43 to 8.83] (p = 0.52) | NA | NA |
| BEVA + FOLFOX vs FOLFOX | 2 [13, 83] | 1885 | 8.63 [− 9.93 to 27.19] (p = 0.36) | 96 | 0.00001 |
| BEVA + CT vs CETUX + CT | 4 [74, 77, 86, 87] | 547 | − 0.52 [− 7.71 to 6.67] (p = 0.89) | 0 | 0.99 |
| BEVA vs no BBP | 5 [42, 73, 81, 84, 85] | 3553 | 4.89 [1.91 to 7.87] (p = 0.001) | 73 | 0.005 |
| Progression-free survival (months) | 11 [42, 71, 74, 76, 78, 81–83, 87, 88] | 3704 | 2.85 [0.74 to 4.96] (p < 0.008) | 90 | 0.00001 |
| BEVA + CT vs CT alone | 4 [71, 78, 82, 88] | 2405 | 2.21 [− 0.06 to 4.48] (p = 0.06) | 70 | 0.002 |
| BEVA + FOLFORI vs FOLFIRI | 1 [76] | 35 | 8.60 [7.52 to 9.68] (p < 0.00001) | NA | NA |
| BEVA + FOLFOX vs FOLFOX | 2 [76, 83] | 247 | 3.72 [− 1.53 to 8.96] (p = 0.16) | 95 | 0.0001 |
| BEVA + CT vs CETUX + CT | 2 [74, 87] | 315 | 2.00 [0.33 to 3.67] (p = 0.04) | 0 | 0.67 |
| BEVA vs no BBP | 2 [42, 81] | 702 | 1.65 [− 3.74 to 7.03] (p = 0.55) | 92 | 0.0003 |
| Post-progression survival (months) | 3 [73, 84, 85] | 2851 | 5.90 [2.59 to 9.21] (p = 0.0005) | 82 | 0.004 |
| BEVA vs no BBP | 3 [73, 84, 85] | 2851 | 5.90 [2.59 to 9.21] (p = 0.0005) | 82 | 0.004 |
| Disease control rate (RECIST) | 5 [74, 77, 80, 83, 88] | 571 | 1.05 [0.98 to 1.12] (p = 0.45) | 10 | 0.18 |
| Metastasectomy rate (%) | 2 [71, 77] | 1897 | 2.01 [1.44 to 2.81] (p < 0.0001) | 0 | 0.87 |
I2 > 50% and a p value of the Chi-square test < 0.10 indicate significant heterogeneity between the studies
BEVA bevacizumab, CETUX cetuximab, CI confidence interval, CT chemotherapy, FOLFIRI folinic acid, 5-fluorouracil, irinotecan, FOLFOX folinic acid, 5-fluorouracil, oxaliplatin, I2 heterogeneity, NA not applicable, no BBP no bevacizumab beyond progression, RECIST Response Evaluation Criteria In Solid Tumors